24 May 2013
Keywords: fda, rejects, novartis, painkiller, prexige, food, drug
Article | 08 October 2007
The US Food and Drug Administration says that Swiss drug major Novartis' COX-2 inhibitor Prexige (lumiracoxib) is not approvable, based ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 October 2007
23 May 2013
© 2013 thepharmaletter.com